On April 2nd, 2013, U.S. President Barack Obama unveiled the “BRAIN” Initiative, which is short for Brain Research through Advancing Innovative Neurotechnologies. The BRAIN Initiative may be known as the spiritual successor to the Human Genome Project, not only for its desire to understand a mysterious place known to medical science, but for taking its cues from the initial success of the HGP.
On March 12, 2013, Acadia Pharmaceuticals (ACAD) reported financial results for the fourth quarter and full year 2012. Total revenues in the quarter were $0.4 million, essentially in-line with our estimate of $0.3 million. Revenues consisted of collaborative payments from Allergan, Inc. (AGN) and other collaboration partners. For the full year 2012, total revenues were $4.9 million.
The Healthcare ecosystem in the United States is changing dramatically due to significant regulations and legislation. Though Obamacare gets the most attention for its impact on patient care and healthcare coverage, legislation such as the Meaningful Use Regulations passed in 2009, followed by the passage of the Affordable Care Act in 2010, and the most recent Sequestration may have a profound impact on the opportunities for developing medical devices and medical device investors.
In Part II of our discussion with DARA Biosciences (NASDAQ: DARA) CEO and Chief Medical Officer Dr. David Drutz, we look into key catalysts for the specialty pharmaceutical company. Dr. Drutz discusses the medical need for the oral-liquid tamoxifen, Soltamox, licensed to DARA by UK-based Rosemont Pharmaceuticals — as well as the market opportunity in developing oncology services.
Intellicell BioSciences (OTC: SVFC) has pioneered a unique method of acquiring stromal vascular fraction cells derived from the blood vessels in the adult adipose tissue. The company’s proprietary protocol can separate adult autologous VFC cells from the adipose tissue without the use of enzymes.
NPS Pharmaceuticals expects an FDA decision under the Prescription Drug User Fee Act (PDUFA) on the approval status of GATTEX, being developed for the treatment of adult short bowel syndrome.
Arena and Vivus’ approval of their obesity drugs — the first such approved in 13 years — have sent shockwaves throughout the industry. With Orexigen’s drug on the way, these have the potential to dramatically alter an entire sub-sector once left for dead. Still, despite positive data and FDA support, these drugs did not reach approval phase without several speed bumps along the way. And more questions are yet to come.
At OneMedPlace, our goal is to be your eyes and ears to the biotech and life sciences sector: putting into perspective what we’ve seen so far, and providing you with snapshots of and what’s upcoming.
The Food and Drug Administration must act quickly to enforce a largely ignored 35-year-old mandate prohibiting non-medical use of antibiotics in farm animals.
IntelGenx is at the forefront of the industry with CPI-300 being the only single dose 450 mg formulation of Bupropion HCl approved by the FDA.
Copyright © 2025 | WordPress Theme by MH Themes